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Background: The extended Consolidated Standards of Reporting Trials (CONSORT) Statement for Abstracts was
developed to improve the quality of reports of randomized controlled trials (RCTs) because readers often base their
assessment of a trial solely on the abstract. To date, few data exist regarding whether it has achieved this goal. We
evaluated the extent of adherence to the CONSORT for Abstract statement for quality of reports on RCT abstracts
by four high-impact general medical journals.
Methods: A descriptive analysis of published RCT abstracts in The New England Journal of Medicine (NEJM), The
Lancet, The Journal of American Medical Association (JAMA), and the British Medical Journal (BMJ) in the year 2010
was conducted by two reviewers, independently extracting data from a MEDLINE/PubMed search.
Results: We identified 271 potential RCT abstracts meeting our inclusion criteria. More than half of the abstracts
identified the study as randomized in the title (58.7%; 159/271), reported the specific objective/hypothesis
(72.7%; 197/271), described participant eligibility criteria with settings for data collection (60.9%; 165/271), detailed the
interventions for both groups (90.8%; 246/271), and clearly defined the primary outcome (94.8%; 257/271). However, the
methodological quality domains were inadequately reported: allocation concealment (11.8%; 32/271) and details of
blinding (21.0%; 57/271). Reporting the primary outcome results for each group was done in 84.1% (228/271). Almost all
of the abstracts reported trial registration (99.3%; 269/271), whereas reports of funding and of harm or side effects from
the interventions were found in only 47.6% (129/271) and 42.8% (116/271) of the abstracts, respectively.
Conclusions: These findings show inconsistencies and non-adherence to the CONSORT for abstract guidelines, especially
in the methodological quality domains. Improvements in the quality of RCT reports can be expected by adhering to
existing standards and guidelines as expressed by the CONSORT group.
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Randomized controlled trials (RCT) are considered evi-
dence of the highest grade in the hierarchy of research
designs [1]. Because these reports can have a powerful and
immediate impact on patient care, accurate and complete
reporting concerning the design, conduct, analysis, and
generalizability of the trial should be conveyed [2].* Correspondence: jcb77@cnu.ac.kr
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reproduction in any medium, provided the orInterpretation of RCT results becomes difficult, if not im-
possible, with inadequate reports causing biased results to
receive false reliability [3]. Thus, adequate reporting is
essential for the reader in evaluating how a clinical trial
was conducted and in judging its validity [4].
Regarding the methodological details in describing
medical research, focusing on RCTs [5], the most prom-
inent guideline, the Consolidated Standards of Reporting
Trials (CONSORT), was published [2] and has been
updated regularly [3,6,7]. Because abstracts are the only
substantive portion of a paper that many readers read,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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content of the article. Thus, the International Committee
of Medical Journal Editors (ICMJE) emphasized that arti-
cles reporting clinical trials should contain abstracts that
include CONSORT items identified as essential [8]. Pre-
liminary appraisals suggest that the use of CONSORT
items is associated with improvements in the quality of
RCTs being reported [9]. Nevertheless, inconsistent [10]
and suboptimal [11,12] results have also been found. With
respect to the recent recommendations from CONSORT
for Abstracts [7], the reporting quality of RCT abstracts
published in four major general medical journals, The
Journal of American Medical Association (JAMA), British
Medical Journal (BMJ), The Lancet, and The New England
Journal of Medicine (NEJM) in 2006 was found to be sub-
optimal [12]. This evaluation will offer an update as to
whether CONSORT for Abstracts improves the quality of
reports, given the suboptimal reporting by these highly
esteemed journals.
Adherence to CONSORT requires continual appraisal
for improving the precision and transparency of pub-
lished trials. Consequently, in an effort to promote qual-
ity reports of RCT abstracts, we evaluated the extent of
adherence to the CONSORT for Abstracts statement for
quality of reports in four high-impact general medical
journals published during the year 2010.
Methods
Data sources
We selected four high-impact general medical journals:
JAMA, BMJ, The Lancet, and NEJM. These journals
endorsed the CONSORT in 1996, except the NEJM,
which did so in 2005 [10]. Under the article submission
instructions for the authors, the two journals, BMJ
and The Lancet, clearly recommended following the
CONSORT for Abstracts guidelines, whereas JAMA
and NEJM referred to the ICMJE’s ‘Uniform Requirements
for Manuscripts Submitted to Biomedical Journals’ where
the abstract section is required to prepare in accordance
with the CONSORT for Abstracts guidelines [13-16]. We
conducted a MEDLINE/PubMed search to identify all
RCTs published between January and December 2010 with
the following search strategy: “Lancet” [Jour] OR
“JAMA”[Jour] OR “The New England journal of Medici-
ne”[Jour] OR “BMJ”[Jour] AND (Randomized Controlled
Trial[ptyp] AND medline[sb] AND (“2010/01/01”[PDAT] :
“2010/12/31”[PDAT])).
Study selection
RCT abstracts of preventive and therapeutic interven-
tions were selected. We included abstracts in which the
allocation of participants to interventions was described
by the words random, randomly allocated, randomized,
or randomization. However, the abstracts of other studydesigns were excluded: observational studies, economic
analyses on RCTs, quasi-randomized trials, cluster ran-
domized trials, diagnostic or screening tests, follow-up
studies of previously reported RCTs, editorials, and letters.
The modified CONSORT extension for cluster rando-
mized trials [17] and separate Standards for the Reporting
of Diagnostic Accuracy (the STARD) statement for report-
ing studies of diagnostic tests [18] prevented us from
including these studies.
Data extraction
Two reviewers (SG and EjK) underwent training in evalu-
ating RCTs using the CONSORT for Abstracts [7] and
begun the data extraction. A ‘yes’ or ‘no’ answer was
assigned for each item indicating whether the author had
reported it. A pilot study was performed with randomly
selected abstracts to assess inter-observer agreement using
the kappa value [19] and to resolve any discrepancies dur-
ing the independent data-extraction process. With the
assurance of uniformity in the interpretation, the data
extraction process was carried out in duplicate for the
remaining abstracts.
The data extraction items included the following
descriptive information: name of the journal, author
addresses including postal address, email or telephone
numbers, and medical specialties (e.g. clinical/primary
care, surgical/anesthesiology, gynecology/obstetrics, on-
cology, psychiatry, pediatrics); trial design (e.g., parallel,
factorial, superiority, non-inferiority, crossover). Addition-
ally, the following criteria were applied: mentioned rando-
mized or randomly allocated in title, abstract, or both;
defined the objective/hypothesis (e.g., to compare the
effectiveness of A with B for condition C) or brief back-
ground if lacking an objective/hypothesis; identified par-
ticipant eligibility criteria, settings of data collection, or
both; identified interventions intended for each group
(intervention and control group); defined primary out-
come of the trial; described methods of random sequence
generation; described blinding/masking using a generic
(simply stating single-blind or double-blind) or detailed
(explanation blinding between patients and caregivers,
investigators, or outcome assessors) description; provided
number of participants randomized and analyzed in each
group; identified trial status (whether complete or stopped
prematurely); included primary outcome for each group
and the estimated effect size with its precision (confidence
interval); explained harm reporting; provided conclusions
with general interpretation of results or discussed benefit
and risks from the intervention; provided information on
trial registration and funding. Finally, the abstract format
(structured or unstructured) was recorded.
Regarding the assessment of the abstract quality domain,
the following characteristics were identified: allocation
concealment (simply mentioned or briefly explained the















NEJM IMRAD+ 53.5 128 (38.6) 113 (41.7)








13.5 61 (18.4) 35 (12.9)
*JCR 2010 Impact factor; +introduction/background, method, results, and
discussion format; ++objective, design, setting, participants, intervention, main
outcome measure, results, and conclusions format.
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telephone or Internet-based system, computer-generated
randomization sequence, permuted blocks, sealed envelope
with stratification) and blinding (as mentioned above).
Data analysis
Data for descriptive statistics were analyzed using
Microsoft Excel 2007 and the SPSS software (ver. 19.0,
IBM SPSSW). We determined the overall number and
proportion (%) of RCT abstracts that included each of
the items recommended by CONSORT for Abstracts.
The kappa statistic was used to measure chance-adjusted
inter-observer agreement for reporting aspects of trial
quality and significance of results.
Results
Our search strategy identified 332 RTC abstracts from
the four high-impact general medical journals during the
initial search. Of these, 61 RCT abstracts (10 observa-
tional studies, 7 economic analyses, 20 cluster RCTs, 8
diagnostic tests, 1 quasi-randomized trial, 4 follow-up
studies, 5 editorials and letters, and 6 cohort studies)
were excluded, as shown in Figure 1. Finally, in total,
271 RCT abstracts were selected for the analysis.
Study characteristics
The numbers of RCTs published in the four high-impact
general medical journals are shown in Table 1. Among
the 271 included RCT abstracts, 41.7% (113/271) were
published in NEJM, followed by Lancet 29.5% (80/271),
JAMA 15.9% (43/271), and BMJ 12.9% (35/271). All
these journals adopted structured abstract formats:
IMRAD (introduction/background, method, results, and
discussion) in NEJM and Lancet, and an eight-heading
format (objective, design, setting, participants, interven-
tion, main outcome measure, results, and conclusions)
in JAMA and BMJ [20].Relevant RCT abstracts identified from 
MEDLINE/ PubMed search (n= 332)
RCT abstracts included for 
analysis (n= 271) 
Data extraction in duplicates, entry 
and analysis 
Figure 1 Flow chart of studies considered for inclusion.Reporting of general items
Table 2 shows the assessment of CONSORTchecklist items
reported in the 271 included RCTs. Almost all RCTs
(98.9%; 268/271) identified “randomized” in the abstract,
but only 58.7% (159/271) reported the same in the title;
among these, reporting by NEJM was very low (4.4%;
5/113) compared with the other journals. Of the included
abstracts, 70.5% (191/271) provided the authors’ postal and
email addresses. Just 23.3% (63/271) of these RCT abstracts
provided a description of the trial design (parallel, factorial,
crossover, etc.).Reporting of trial methodology
In total, 60.9% (165/271) of the abstracts reported both
eligibility criteria of participants and settings of data col-
lection; among these, NEJM reporting was only 25.7%
(29/113). In contrast, 99.3% (269/271) reported only the
eligibility criteria of participants. Most of the abstracts
(90.8%; 246/271) described details of the intervention in-
cluding denomination, usage, and course of treatmentExcluded abstracts: 61 
Observational studies (n= 10) 
Economic analysis (n= 7) 
Cluster RCTs (n= 20) 
Diagnostic tests (n= 8) 
Quasi- randomized (n= 1) 
Follow-up studies (n= 4) 
Editorials and letters (n= 5) 
Cohort (n= 6) 
Table 2 CONSORT checklist items for assessment from abstracts of included RCTs
Items Assessment criteria Assessment of individual journals, n (%) Overall, n (%)
(n=271)NEJM (n=113) Lancet (n=80) JAMA (n=43) BMJ (n=35)
Title Study identified as randomized in title 5 (4.4) 79 (98.6) 41 (95.3) 34 (97.1) 159 (58.7)
Mentioned random/randomized in
abstract
110 (97.3) 80 (100) 43 (100) 35 (100) 268 (98.9)
Authors Addresses including postal and emails 75 (66.4) 54 (67.5) 33 (76.7) 29 (82.9) 191 (70.5)
Only postal address 24 (21.2) 26 (32.5) 7 (16.3) 6 (17.1) 64 (23.6)
Trial design Descriptions provided (parallel, factorial,
crossover, etc.)
21 (18.6) 23 (28.8) 9 (20.9) 10 (28.6) 63 (23.3)
Methods
Participants Eligibility criteria with settings of data
collection
29 (25.7) 61 (76.3) 40 (93.0) 35 (100) 165 (60.9)
Only eligibility criteria provided 111 (98.2) 80 (100) 43 (100) 35 (100) 269 (99.3)
Interventions Details including denomination, usage,
course of treatment for both groups
97 (85.8) 74 (92.5) 40 (93.0) 35 (100) 246 (90.8)
Objective Specific objective/hypothesis 40 (35.4) 80 (100) 42 (97.7) 35 (100) 197 (72.7)
Only background described 73 (64.6) - 1 (0.9) - 74 (27.3)
Outcome Clearly defined primary outcome 99 (87.6) 80 (100) 43 (100) 35 (100) 257 (94.8)
Randomization Reported the method of random
sequence generation
8 (7.1) 71 (88.6) 3 (7.0) 2 (5.7) 84 (31.0)
Allocation concealment - 31 (38.6) - 1 (2.9) 32 (11.8)
Blinding Generic description* 40 (35.4) 26 (32.5) 20 (46.5) 16 (45.7) 102 (37.6)




Number of participants randomized in
each group
58 (51.3) 79 (98.6) 32 (74.4) 22 (62.9) 191 (70.5)
Numbers
analyzed
Number of participants analyzed for each group 58 (51.3) 77 (96.3) 30 (69.8) 21 (60.0) 186 (68.7)
Outcomes Primary outcome result for each group 87 (76.9) 78 (97.5) 39 (90.7) 24 (68.6) 228 (84.1)
For primary outcome, effect size and
confidence interval reported (in total)
35 (31.0) 54 (67.5) 24 (55.8) 15 (42.9) 128 (47.2)
Effect size and confidence interval
(trials with binary outcome)
26 (out of 50)
(52.0)
33 (out of 45)
(73.3)
12 (out of 19)
(63.2)
10 (out of 15)
(66.7)
81 (out of 127)
(63.8)
Effect size and confidence interval
(trials with continuous outcome)
0 (out of 8) 8 (out of 13)
(61.5)
5 (out of 10)
(50.0)
2 (out of 6)
(33.3)
15 (out of 37)
(40.5)
Harms Adverse event or side effect reported 53 (46.9) 50 (62.5) 7 (16.3) 6 (17.1) 116 (42.8)
Conclusions Discussed benefit or harm from
the intervention
28 (24.8) 13 (16.3) 5 (11.6) 9 (25.7) 55 (20.3)
Stated only the benefit from the
intervention
84 (74.3) 65 (81.3) 38 (88.4) 25 (71.4) 212 (78.2)
Trial registration Reported registration number and name
of trial register
113 (100) 78 (97.5) 43 (100) 35 (100) 269 (99.3)
Funding Reported the source of funding 52 (46.0) 77 (96.3) - - 129 (47.6)
*Simply stating single-blind or double-blind; ++blinding explained between patients and caregivers, investigators, or outcome assessors.
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tioned in 72.7% (197/271), with the remaining 27.3%
(74/271) reporting a background or rationale for the study
rather than an objective/hypothesis as recommended by
CONSORT. This was clearly seen in the NEJM data: only
35.4% (40/113) of abstracts had clear objectives, compared
with 97.7% (42/43) in JAMA and 100% in both Lancet
(80/80) and BMJ (35/35). Reporting of a clearly definedprimary outcome occurred in 94.8% (257/271) of abstracts
overall: it occurred in 100% of abstracts in three of the
journals but only 87.6% (99/113) of those in NEJM. Only
31% (84/271) of abstracts mentioned the method of ran-
dom sequence generation, with better reporting in Lancet
(88.6%; 71/80) than in the other journals. Kappa values for
methods (participants, interventions, objective, outcome,
and randomization) were 0.88 or above.
Table 3 Assessment of CONSORT checklist items using an
equal proportion of abstracts per journal (n=35)
Items Assessment criteria Overall, n (%)
(n=140)
Title Study identified as randomized
in title
104 (74.3)
Authors Addresses including postal
and emails
107 (76.4)
Trial design Descriptions provided (parallel,
factorial, crossover, etc.)
30 (21.4)
Participants Eligibility criteria with settings of
data collection
101 (72.1)
Interventions Details including denomination,
usage, course of
treatment for both groups
133 (95.0)
Objective Specific objective/hypothesis 118 (84.3)
Outcome Clearly defined primary outcome 137 (97.9)
Randomization Reported the method of
random sequence generation
42 (30.0)
Allocation concealment 13 (9.3)








Number of participants analyzed
for each group
97 (69.3)
Outcomes Primary outcome result for each
group
115 (82.1)
Harms Adverse event or side effect
reported
45 (32.1)
Conclusions Discussed benefit or harm from
the intervention
31 (22.1)
Trial registration Reported registration number
and name of trial register
139 (99.3)
Funding Reported the source of funding 54 (38.6)
*Blinding explained between patients and caregivers, investigators, or
outcome assessors.
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From 271 included abstracts, 70.5% (191/271) reported
the number of participants randomized to each group,
and 68.7% (186/271) reported the number of participants
included for analysis (kappa, 0.66 and 0.80). A total of
84.1% (228/271) of abstracts reported the results for the
primary outcome measure for each group; however, BMJ
reported this value in only 68.6% (24/35) and NEJM 76.9%
(87/113), compared with two other journals, which had
reporting rates above 90%. The proportion of abstracts
describing effect size (ES) and confidence intervals (CI) for
the primary outcome was 47.2% (128/271); 63.8% (81 out
of 127 trials with binary outcomes) and 40.5% (15 out of
37 trials with continuous outcome) reported both ES and
CI. Adverse events or side effects of the intervention were
reported in 42.8% (116/271) of abstracts. Inter-observer
agreement on abstract reporting of results was 0.86 or
above.
Reporting of conclusions
Regarding the conclusions section of the abstracts, only
20.3% (55/271) stated the benefits and harm from the
therapy, in contrast to the 72.8% (212/271) of abstracts
that reported only benefits. Overall, most of the RCTs
reviewed (99.3%; 269/271) reported that the trial was
registered, and 47.6% (129/271) reported funding; how-
ever, no abstracts in JAMA or BMJ reported funding.
Kappa values for conclusions, trial registration, and
funding were 0.95 or above.
Reporting of trial quality
In total, 11.8% (32/271) of the abstracts mentioned
details of allocation concealment, but this information
was lacking from abstracts in NEJM and JAMA. With
respect to blinding, 37.6% (102/271) mentioned it in
generic terms as single blind or double blind, and 21%
(57/271) described blinding in detail. Kappa values for
quality domains were 0.82 or above.
Assessing methodology using equal proportion of
abstracts per journal
An additional analysis to assess the CONSORT checklist
items using an equal proportion of abstracts per journal
was carried out. Since BMJ constituted the lowest number
of abstracts (n=35), we selected an equal number of RCT
abstracts from each journal using a computer-generated
simple random sampling method. Table 3 shows the
reporting of methodological quality or key features of trial
designs and trial results using an equal proportion of
abstracts per journal. The details of trial design were
included in 21.4% (30/140), reporting of method of ran-
dom sequence generation in 30.0% (42/140), allocation
concealment in 9.3% (13/140), details of blinding in 20.7%
(29/140), number of participants analyzed for each groupin 69.3% (97/140), and primary outcome result for each
group in 82.1% (115/140).
Discussion
We carried out a descriptive cross-sectional study to as-
sess the quality of abstracts for reports of randomized
controlled trials from four high-impact general medical
journals published in the year 2010, that is, after the
release of the CONSORT for Abstracts guidelines in 2008
[7]. Some of the checklist items such as participant eligi-
bility criteria, details of intervention, definition of primary
outcome, reporting of primary outcome results for each
group, and trial registration were adequately reported.
However, harm and funding were reported in fewer than
50.0% of these abstracts. This inadequate reporting is con-
sistent with previous findings for reporting harm [12,21]
and funding [21,22]. Two journals, JAMA and BMJ, did
not report the source of funding, probably reflecting more
of the house style of these journals [13,15].
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domains were still inadequately reported, with no sign of
improvement despite the CONSORT recommendations.
Table 4 shows a comparison between the assessment of
methodological quality domains in the current study and
results of a similar study performed previously in relation
to the endorsement of CONSORT for abstracts. As com-
pared to other studies, reporting of allocation concealment
(11.8%) and details of blinding (21.0%) is higher but still
suboptimal in the current study. Abstract reporting is often
subject to space constraints and journal formats, which
may lead to disparities between full paper results and
abstract results. However, a previous study showed that
with a word limit of 250–300 words, the checklist items
can easily be incorporated [23]. Nevertheless, when an
abstract lacks key details about a trial, the assessment of
the validity and the applicability of the results become
difficult.
We also assessed reporting of checklist items for indi-
vidual journals to compare adherence patterns between
journals. Although NEJM and Lancet both adopted the
IMRAD abstract format, reporting of the specific object-
ive/hypothesis was minimal in NEJM (35.4%), with only
background descriptions in 64.6% of abstracts. NEJM has
a very specific style for reporting background rather than
objectives [16]; thus, the findings here reflect the specific
house style of the journal rather than implementation of
the CONSORT for Abstracts guideline. Similarly, for the
methodological quality domain, reporting in NEJM and
JAMA was 0% for the allocation concealment item, a
value comparable to that found in a Chinese study [26].
Funding was also reported in 0% of abstracts in JAMA
and BMJ. It has previously been shown that studies
funded by pharmaceutical companies have four times the
odds of having outcomes favorable to the sponsor than do
studies funded by other sources, causing publication bias
[27]. Regarding the reporting of conclusions, all four jour-
nals failed to provide a balanced summary that noted both
benefits and harm from the interventions (11.6%–25.7%),Table 4 Comparison of methodological quality domains









32 (11.8) 84 (31.0) 102 (37.6) 57 (21.0)
Mann (2011)
(n=129) [24]
- 0 (0.0) - 21 (16.3)
Wang (2010)
(n=345) [22]
0 (0.0) 17 (4.9) 39 (11.3) 1 (0.3)
Berwanger (2009)
(n=227) [12]
1 (0.4) - 92 (40.5) 21 (9.2)
Hopewell (2006)
(n=37) [25]
0 (0.0) 26 (70.3) - 6 (16.2)an unsatisfactory value compared with the results from a
Chinese study (1.0%) [22]. Between-journal assessments
also showed that responses to most of the checklist items
were suboptimal for NEJM; these results were consistent
with past studies [5,28]. In this inadequate reporting of
trials, one positive reporting domain was identified by this
study: trial registration, which was reported at a rate of
97.5% by Lancet and 100% by the other three journals.
The World Health Organization (WHO), facilitating inter-
national collaboration by establishing a clinical trials regis-
try platform [29], and ICMJE’s strict policy of considering
trials for publication only if they are registered [30] were
likely influences.
Our study has some limitations. Assessment of specia-
lized journals was beyond the scope of this study. Also, we
assessed only structured abstracts. Although some studies
have suggested that the adoption of structured abstracts by
the journals can improve the reporting of trials [31-33], the
findings from our study suggest otherwise. The sample of
abstracts is influenced by one journal, the NEJM (41.7% of
the overall sample); however, a similar trend occurred in
2006 showing the influence of NEJM (41.9%) on overall
findings [12]. Moreover, our finding reflects the cross-
sectional design. Also, NEJM often published the largest
number of RCTs among the other three journals [34]. To
minimize the impact of disproportionate abstract samples
per journal, we carried out an additional analysis using an
equal proportion of abstracts per journal, but the findings
were similar with respect to reporting of methodological
quality or key features of trial designs and trial results. The
analytical strategy known as intention-to-treat (ITT), con-
sidered as an optimal approach for preserving the integrity
of randomization [35], has been advocated in the full
CONSORT 2010 updated guideline [6]; however, this
approach has not been incorporated in the CONSORT for
Abstracts guideline. Thus, we did not consider inclusion of
ITT approach in our assessment. Despite this, our study
has several strengths. We reviewed a large number of RCT
abstracts published in four high-impact major general
medical journals that have universal acceptance among the
medical research community. We also conducted an
objective data-extraction process, with the domains that
were included in the abstracts marked as ‘yes’ and those
not reported as ‘no’ based on standard checklist items
recommended by the CONSORT group and without
reviewer inference. Thus, this study’s methodology is
reproducible. Additionally, the period after the CONSORT
for Abstracts guidelines were published provides an ad-
equate time frame for the dissemination and endorsement
of the CONSORT statement by the research community.
Conclusions
The findings from our study demonstrate inconsistencies
and patterns of non-adherence to the CONSORT for
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quality domains. CONSORT is an evolving guideline
[6,36] not considered to be an absolute standard. How-
ever, improvements in the quality of RCT reports can be
expected by adherence, on the parts both of authors and
journal editors during peer review, to existing standards
and guidelines as expressed by the CONSORT group.
We hope that this will occur in the future.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SG and EjK both participated in the design, conduct, assessment, and
drafting of the manuscript. EyK and WK conceived the study, interpreted the
data, and revised the manuscript. All authors read and approved the final
manuscript.
Author details
1Department of Clinical Pharmacy, College of Pharmacy, Chungnam National
University, 99, Dehak-ro, Yuseong-gu, Daejeon 305-764, South Korea. 2College
of Pharmacy, Yeungnam University, Kyoungbuk, 712-749, South Korea.
Received: 9 January 2012 Accepted: 27 April 2012
Published: 7 June 2012
References
1. Concato J, Shah N, Horwitz RI: Randomized, controlled trials,
observational studies, and the hierarchy of research designs. N Engl J
Med 2000, 342:1887–1892.
2. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D,
Schulz KF, Simel D, Stroup DF: Improving the quality of reporting of
randomized controlled trials. The CONSORT statement. JAMA 1996,
276:637–639.
3. Moher D, Schulz KF, Altman DG: The CONSORT statement: revised
recommendations for improving the quality of reports of parallel-group
randomized trials. Ann Intern Med 2001, 134:657–662.
4. Sanchez-Thorin JC, Cortes MC, Montenegro M, Villate N: The quality of
reporting of randomized clinical trials published in Ophthalmology.
Ophthalmology 2001, 108:410–415.
5. Kane RL, Wang J, Garrard J: Reporting in randomized clinical trials
improved after adoption of the CONSORT statement. J Clin Epidemiol
2007, 60:241–249.
6. Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC, Devereaux PJ,
Elbourne D, Egger M, Altman DG: CONSORT 2010 Explanation and
Elaboration: Updated guidelines for reporting parallel group randomised
trials. J Clin Epidemiol 2010, 63:e1–e37.
7. Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz
KF: CONSORT for reporting randomized controlled trials in journal and
conference abstracts: explanation and elaboration. PLoS Med 2008, 5:e20.
8. Uniform requirements for manuscripts submitted to biomedical journals:
Writing and editing for biomedical publication. J Pharmacol Pharmacother
2010, 1:42–58.
9. Plint AC, Moher D, Morrison A, Schulz K, Altman DG, Hill C, Gaboury I: Does
the CONSORT checklist improve the quality of reports of randomised
controlled trials? A systematic review. The Medical Journal of Australia
2006, 185:263–267.
10. Folkes A, Urquhart R, Grunfeld E: Are leading medical journals following their
own policies on CONSORT reporting? Contemp Clin Trials 2008, 29:843–846.
11. Mills EJ, Wu P, Gagnier J, Devereaux PJ: The quality of randomized trial
reporting in leading medical journals since the revised CONSORT
statement. Contemp Clin Trials 2005, 26:480–487.
12. Berwanger O, Ribeiro RA, Finkelsztejn A, Watanabe M, Suzumura EA, Duncan BB,
Devereaux PJ, Cook D: The quality of reporting of trial abstracts is suboptimal:






17. Campbell MK, Elbourne DR, Altman DG: CONSORT statement: extension to
cluster randomised trials. BMJ (Clinical Research ed) 2004, 328:702–708.
18. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM,
Moher D, Rennie D, de Vet HC, Lijmer JG: The STARD statement for
reporting studies of diagnostic accuracy: explanation and elaboration.
Clinical Chemistry 2003, 49:7–18.
19. Viera AJ, Garrett JM: Understanding interobserver agreement: the kappa
statistic. Family Medicine 2005, 37:360–363.
20. Nakayama T, Hirai N, Yamazaki S, Naito M: Adoption of structured abstracts
by general medical journals and format for a structured abstract. Journal
of the Medical Library Association: JMLA 2005, 93:237–242.
21. Xu L, Li J, Zhang M, Ai C, Wang L: Chinese authors do need CONSORT:
reporting quality assessment for five leading Chinese medical journals.
Contemporary clinical trials 2008, 29:727–731.
22. Wang L, Li Y, Li J, Zhang M, Xu L, Yuan W, Wang G, Hopewell S: Quality of
reporting of trial abstracts needs to be improved: using the CONSORT
for abstracts to assess the four leading Chinese medical journals of
traditional Chinese medicine. Trials 2010, 11:75.
23. Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF:
CONSORT for reporting randomised trials in journal and conference
abstracts. Lancet 2008, 371:281–283.
24. Mann E, Meyer G: Reporting quality of conference abstracts on
randomised controlled trials in gerontology and geriatrics: a cross-
sectional investigation. Zeitschrift fur Evidenz, Fortbildung und Qualitat im
Gesundheitswesen 2011, 105:459–462.
25. Hopewell S, Clarke M, Askie L: Reporting of trials presented in conference
abstracts needs to be improved. Journal of Clinical Epidemiology 2006,
59:681–684.
26. Zhang D, Yin P, Freemantle N, Jordan R, Zhong N, Cheng KK: An
assessment of the quality of randomised controlled trials conducted in
China. Trials 2008, 9:22.
27. Lexchin J, Bero LA, Djulbegovic B, Clark O: Pharmaceutical industry
sponsorship and research outcome and quality: systematic review.
BMJ (Clinical research ed) 2003, 326:1167–1170.
28. Moher D, Jones A, Lepage L: Use of the CONSORT statement and quality of
reports of randomized trials: a comparative before-and-after evaluation.
JAMA: the Journal of the American Medical Association 2001, 285:1992–1995.
29. Gulmezoglu AM, Pang T, Horton R, Dickersin K: WHO facilitates
international collaboration in setting standards for clinical trial
registration. Lancet 2005, 365:1829–1831.
30. De Angelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, Kotzin S,
Laine C, Marusic A, Overbeke AJ, et al: Is this clinical trial fully registered?
A statement from the International Committee of Medical Journal
Editors. Lancet 2005, 365:1827–1829.
31. Hopewell S, Eisinga A, Clarke M: Better reporting of randomized trials in
biomedical journal and conference abstracts. Journal of Information
Science 2007, 34:162–173.
32. Taddio A, Pain T, Fassos FF, Boon H, Ilersich AL, Einarson TR: Quality of
nonstructured and structured abstracts of original research articles in
the British Medical Journal, the Canadian Medical Association Journal
and the Journal of the American Medical Association. CMAJ: Canadian
Medical Association journal = Journal de l’Association Medicale Canadienne
1994, 150:1611–1615.
33. Dupuy A, Khosrotehrani K, Lebbe C, Rybojad M, Morel P: Quality of abstracts in
3 clinical dermatology journals. Archives of Dermatology 2003, 139:589–593.
34. Hildebrandt M, Vervolgyi E, Bender R: Calculation of NNTs in RCTs with
time-to-event outcomes: a literature review. BMC Medical Research
Methodology 2009, 9:21.
35. Polit DF, Gillespie BM: Intention-to-treat in randomized controlled trials:
recommendations for a total trial strategy. Research in Nursing and Health
2010, 33:355–368.
36. Schulz KF, Altman DG, Moher D: CONSORT 2010 Statement: updated
guidelines for reporting parallel group randomised trials. Trials 2010, 11:32.
doi:10.1186/1745-6215-13-77
Cite this article as: Ghimire et al.: Assessment of adherence to the
CONSORT statement for quality of reports on randomized controlled
trial abstracts from four high-impact general medical journals. Trials
2012 13:77.
